Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinetic considerations.
Bone infection has long been a formidable foe of orthopaedic surgeons. The standard method of treating osteomyelitis generally consists of irrigation and debridement supplemented by pre- and postoperative antibiotics and intraoperative antimicrobial solutions. In the 1970s, Buchholz introduced the concept of local antibacterial therapy in the form of antibiotic impregnated bone cement to treated infected arthroplasties. From this, antibiotic impregnated beads were developed to treat local infections of bone and soft tissue. The advantage of these beads compared with parenteral therapy is that they deliver a high concentration of antibacterial locally while avoiding high systemic concentrations, thus avoiding adverse effects that are often associated with parenteral antibacterial therapy. Additionally, methylmethacrylate bone cement does not significantly affect the immune response of the body. This makes the use of antibiotic-impregnated polymethylmethacrylate (PMMA) beads highly effective either as an alternative to, or in conjunction with, systemic antibiotic treatment of infected arthroplasties, and localised bone and soft tissue infection. This article explores the indications for the use of local therapy as well as any advantages or disadvantages it may have over systemic antibacterial treatment. Additionally, there are important pharmacokinetic considerations for the optimal use of antibacterial agents in the treatment of osteomyelitis.
Henry
S L
SL
Department of Orthopaedic Surgery, School of Medicine, University of Louisville, Kentucky, USA.
Galloway
K P
KP
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001843:Bone Cements / Q000378:metabolism; D001847:Bone Diseases / Q000188:drug therapy*; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D016503:Drug Delivery Systems; D006801:Humans; D008768:Methylmethacrylates / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D008863:Microspheres; D010019:Osteomyelitis / Q000188:drug therapy*; D010406:Penicillins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D018461:Soft Tissue Infections / Q000188:drug therapy*; D014640:Vancomycin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001843:Bone Cements; D002511:Cephalosporins; D008768:Methylmethacrylates; D010406:Penicillins; D014640:Vancomycin